Synergia Medical, a preclinical medical device company, today announced the successful completion of a €9 million Series B funding round.
BRUSSELS, BELGIUM, September 12, 2022 /EINPresswire.com/ — Drug Resistant Epilepsy Treatment
SYNERGIA MEDICAL SUCCESSFULLY RAISES SERIES B FUNDING OF €9 MILLION
This financing assures the First-In-Human implantation of the NAO.VNS in 2023
Belgium, September 12, 2022 – Synergia Medical, a preclinical medical device company that has developed NAO.VNS (Vagus Nerve Stimulation), the first non-metal optoelectronic neurostimulator for the treatment of drug-resistant epilepsy, today announced the successful completion of a €9 million Series B funding round. This allows Synergia Medical to prepare for First-In-Human clinical trials planned for 2023 and the IDE (Investigational Device Exemption) submission to the FDA in the USA. IDE allows an investigational device to be used in a clinical study to collect safety and efficacy data.
This financing was realized with a pool of historical private shareholders, Newton Biocapital, public investors (SFPI, SRIW Life Sciences, Investsud), the support of the Walloon region and joined in this latest round by the institutional investor TheClubDeal, specializing in the life sciences, technology and Smart Living sectors.